Brainstorm increases commercial manufacturing capacity; granted gmp certification for a second production site in israel

New york, july 27, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received good manufacturing practice (gmp) approval from the israel ministry of health for three state-of-the-art cleanrooms leased by the company at the tel aviv sourasky medical center ("sourasky hospital") in tel aviv, israel. the gmp approval confirms that these cleanrooms are compliant with israeli gmps, which are aligned with european union (eu) gmps, and more than doubles the company's capacity to manufacture and ship nurown® into the eu and local israeli markets.
BCLI Ratings Summary
BCLI Quant Ranking